market perform
reason report
epo decis avert worst lift overhang upgrad
bottom line opposit hear today european patent
offic hagu rule narrow auxiliari claim rubraca
novel invent result remov near-term
intellectu properti ip overhang view importantli
narrow patent substanti similar us camsyl crystal
salt patent view base feedback medacorp kol
see european case law skeptic polymorph/
salt patent case us therefor find
invent similar patent enhanc confid
us patent estat upgrad op believ
chanc brand exclus worst
case us extend best case
model result per share fundament valu also see
return option share follow gsk acquisit
tsro assum valu approxim doubl
fundament valu new pt blend fundament
valu option valu result new per share pt
patent decis hue base case lift overhang upgrad
op european patent offic epo opposit divis narrow
broad claim challeng patent expect found
first auxiliari claim cover crystallin camsyl salt form rucaparib
three distinct x-ray defract xrd peak patent
render patent substanti similar in-forc us crystal
camsyl salt ip offer viabl protect decis lift
near-term ip overhang allow share trade fundament
valu also potenti benefit return option
acquisit tsro mp
upgrad outperform new pt base
outcom epo panel believ probabl
rubraca brand exclus last worst case
probabl extend blend scenario
model yield fundament valu approxim per share
also see option return share follow announc
acquisit tsro gsk estim option valu
approxim doubl fundament valu new pt
blend fundament valu option valu
discount rate acquisit
net debt total capit
net debt total capit calcul use bv
compani inform leerink partner llc research
revenu million ep present
pleas refer page import disclosur price chart analyst certif
novelti establish first auxiliari request follow initi
rule main claim novel discuss turn first
auxiliari request narrow claim crystallin camsyl
salt form rucaparib three distinct x-ray defract xrd peak
follow oral present opposit parti clovi
panel held anoth short deliber conclud meet
standard novelti
panel subsequ find suffici invent step first
auxiliari request rule establish novelti panel
focu turn determin whether suffici invent step
establish primari argument opposit focus
throughput screen obvious crystallin camsyl
salt clovi primari argument focus unexpect
remark properti found crystallin camsyl includ
physic chemic stabil solubl compact etc
rel brief deliber minut panel determin
claim amend fulfil invent step argument outcom
in-lin base case scenario medacorp specialist
describ see preview
appeal expect side anticip multi-year process
review outcom morn medacorp specialist
anticip clovi opposit parti like appeal
formal written decis expect epo within next one
two month deadlin file notic appeal approxim two
month appeal claim origin grant patent
remain forc appeal board issu decis view
medacorp kol opposit divis appeal like take
three five year resolv
year price history/av daili volume mil
creat bluematrix
rate share outperform pt clovi commerci stage
biotechnolog compani one product rubraca approv use ovarian cancer
believ stock under-perform last month unexpect
challeng ovarian cancer market well lack takeout option
signific compon investor invest thesi one persist overhang stock
percept compani would acquir concern salt
patent provid ip protect could success challeng given recent
decis europ maintain narrow version camsyl salt patent
increment construct around ip expect share trade closer
arriv new pt
calcul new pt contempl multipl inher uncertainti potenti
impact ip durat perform sensit analysi within model determin
risk-adjust npv share base exclus durat assumpt best worst
base case scenario page chart npv base sensit analysi
assum probabl exclus maintain worst case scenario
probabl exclus maintain consist
camsyl salt patent expiri translat fundament valu addit
see recent tsro acquisit return option space assum similar
takeout premium potenti acquisit probabl occur
result new pt
risk-adjust npv rubraca ip sensit analysi year
commerci risk signific competit parp inhibitor class compet
drug includ astrazeneca/merck lynparza tesaro zejula clinical-stag parp
includ talazoparib veliparib beigen pamiparib among other
commerci execut repres risk current valuat
clinic risk fail clinic trial rubraca includ trial ovarian cancer breast cancer
bladder cancer repres risk current valuat
regulatori risk regulatori reject label expans rubraca earlier line therapi
addit tumor type prostat cancer repres risk current valuat
intellectu properti risk ip clovi invalid earlier anticip would
repres risk pt
mn except per share data
licens mileston revenu
total incom expens net
net incom tax
balanc sheet mn
chang
sec file leerink partner estim
